Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
COVID-19: Ivermectin Prophylaxis in Adult Contacts: First Report on Health Personnel and Post-Exposure Prophylaxis
Chang et al., Research Gate, doi:10.13140/RG.2.2.11985.35680/3 (Preprint)
Chang et al., COVID-19: Ivermectin Prophylaxis in Adult Contacts: First Report on Health Personnel and Post-Exposure.., Research Gate, doi:10.13140/RG.2.2.11985.35680/3 (Preprint)
Jul 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Report on ivermectin post-exposure prophylaxis with 33 patients, showing no cases over 21 days followup.
Chang et al., 21 Jul 2020, retrospective, Peru, preprint, 2 authors.
Contact: timothychang@mednet.ucla.edu, mbutte@mednet.ucla.edu, bpasaniuc@mednet.ucla.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/344251319 COVID-19: IVERMECTIN PROPHYLAXIS IN ADULT CONTACTS. First Report on Health Personnel and Post-Exposure Prophylaxis Preprint · July 2020 DOI: 10.13140/RG.2.2.11985.35680/3 CITATIONS READS 2 21,501 2 authors: Gustavo Aguirre Chang Aurora Natividad Trujillo Figueredo National University of San Marcos SIGESA 136 PUBLICATIONS 105 CITATIONS 125 PUBLICATIONS 31 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: COVID POR VARIANTES DEL SARS COV-2 View project COVID 19 View project All content following this page was uploaded by Gustavo Aguirre Chang on 17 October 2020. The user has requested enhancement of the SEE PROFILE COVID-19: IVERMECTIN PROPHYLAXIS IN ADULT CONTACTS Report on First Cases of Prophylaxis for Healthcare Personnel and PostExposure Prophylaxis Aguirre-Chang, Gustavo and Trujillo Figueredo, Aurora. Research Gate. July 21, 2020 English translation copy edited by Madeline Oh doi: http://dx.doi.org/10.13140/RG.2.2.11985.35680/3 SUMMARY Prophylaxis is aimed at preventing the development of infection and disease after exposure to an infectious agent. The WHO, PAHO and other recognized organizations recommend Post-Exposure Prophylaxis (PEP) for cases of possible infection with HIV, Hepatitis B, C and Tuberculosis. There are also studies that report the use of Ivermectin as prophylaxis for scabies. To date, several studies of PEP in COVID-19 patients using Hydroxychloroquine have been reported, and there are also at least 2 ongoing studies on prophylaxis using Ivermectin. In this article, the first cases in Lima, Perú, of prophylaxis with Ivermectin implemented on healthcare personnel beginning April 7, 2020 are reported and, a study design of PEP with Ivermectin for COVID-19 is also detailed. MATERIALS AND METHODS: For the PEP study, the following protocol was followed: in all persons who qualified as Contacts and tested negative for SARS CoV-2 in the laboratory were given a dose of Ivermectin of 0.2 mg per kilogram of body weight on day one. Additionally, in the men over 45 years of age it was indicated to evaluate giving a second dose of Ivermectin on day 2 or 3, this would be done in case other people in the home or place of residence present characteristic symtoms of COVID-19. The presence of COVID-19 symptoms within the first 3 days of taking Ivermectin was established as the Exclusion Criterion, because the incubation period for COVID-19 is 5 days on average and these patients could have contracted COVID-19 prior to initiation of the study. Daily clinical follow-up was performed for all participants until day 21 after taking Ivermectin. RESULTS: Out of a total of 40 people enrolled, 7 tested positive and were therefore excluded from the study, leaving 33 participants. During the clinical evaluation process of the first 3 days, no person with symptoms of COVID-19 was identified. Therefore no molecular laboratory testing was performed on any participant, no second doses of Ivermectin were indicated, and no participants were excluded from the study. Daily clinical followup was continued for 21 days after taking Ivermectin, and none of the participants exhibited symptoms, nor did they develop COVID-19 disease. CONCLUSION: The result of the present study finds utility in the use of Ivermectin as prophylaxis for COVID-19...
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit